Cyclopharm (ASX:CYC) Other Current Assets: A$1.93 Mil (As of Dec. 2025)


ASX:CYC Cyclopharm Ltd ASX:CYC
45 GF Score
Price A$0.48
GF Value A$0.83
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Cyclopharm Other Current Assets?

Cyclopharm ASX:CYC -4.04% 45 Other Current Assets is A$1.93 Mil as of Dec. 2025. GuruFocus rates ASX:CYC with a GF Score™ of 45/100 and a GF Value™ of A$0.83 (Possible Value Trap). The stock has 7 warning signs investors should review.

Cyclopharm's other current assets for the quarter that ended in Dec. 2025 was A$1.93 Mil.

Cyclopharm's quarterly other current assets increased from Dec. 2024 (A$1.07 Mil) to Jun. 2025 (A$1.21 Mil) and increased from Jun. 2025 (A$1.21 Mil) to Dec. 2025 (A$1.93Mil).

Cyclopharm's annual other current assets increased from Dec. 2023 (A$0.45 Mil) to Dec. 2024 (A$1.07 Mil) increased from Dec. 2024 (A$1.07 Mil) to Dec. 2025 (A$1.93 Mil).


Cyclopharm Other Current Assets Related Terms


Cyclopharm Other Current Assets Historical Data

* Premium members only.

The historical data trend for Cyclopharm's Other Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cyclopharm Other Current Assets Chart

Cyclopharm Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.45 0.57 0.45 1.07 1.93

Cyclopharm Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Current Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.45 0.99 1.07 1.21 1.93
ASX:CYC
45GF Score
Cyclopharm Ltd ASX:CYC
Other Current Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cyclopharm Other Current Assets Calculation

Technically, the other current assets line may include any asset that will be used up within the next 12 months. However, other current assets never include assets that are listed elsewhere in the current assets section of the balance sheet. For this reason, other current assets are almost never:


Cash
Trade Receivables
Inventory

The assets grouped under other current assets are most commonly:


Prepaid Expenses
Tax Assets
Non-Trade Receivables
Other (too numerous to list)

Some companies can and do choose to report each of these items separately.

Other current assets may be made up largely of Prepaid Expenses - unless these are listed on a separate line of the balance sheet.

Prepaid expenses are exactly what they sound like. If a company pays a $30 million insurance premium on the last day of June that will provide coverage for the entire month of July, the company will record a $30 million prepaid expense to account for the insurance expense it will show in July that it already paid for in June.

Tax assets can be quite complex. It is not common for companies to have both tax assets and tax liabilities. It is important that investors take note of both items when considering future taxes.

Non-Trade receivables are rarely a large item. They include money owed to the company by non-customers. Non-trade receivables can be caused by related party transactions, the sale of a business unit, etc. The notes to the company's financial statements will often provide much more detail on this item if it is truly important.

There are a variety of other current assets like non-trade receivables which are simply too numerous to list. If a company is following correct reporting procedures, it should not lump items that are different from one another and yet individually important to the company together under the line Other Current Assets.

At most companies, other current assets are a small and unimportant part of the total balance sheet.

Frequently Asked Questions Learn more about Other Current Assets →
What does a Other Current Assets of A$1.93 Mil mean?
Cyclopharm (ASX:CYC) has a Other Current Assets of A$1.93 Mil as of Dec. 2025. Other current assets as record on a company's balance sheet not categorized as standard assets. View historical data on Cyclopharm.
Is Cyclopharm's Other Current Assets too high?
Cyclopharm's current Other Current Assets is A$1.93 Mil. Overall, Cyclopharm has a GF Score™ of 45/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cyclopharm's Other Current Assets compare to MCK and CAH?
Cyclopharm's Other Current Assets of A$1.93 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Assets for a Medical Distribution company?
A good Other Current Assets depends on the Medical Distribution industry context. However, Other Current Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Assets mean?
A high Other Current Assets can signal that a stock is expensive relative to its fundamentals. Other current assets as record on a company's balance sheet not categorized as standard assets. View historical data on Cyclopharm. Cyclopharm's current Other Current Assets is A$1.93 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cyclopharm stock overvalued right now?
Based on GuruFocus' analysis, Cyclopharm (ASX:CYC) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.83, compared to a current price of A$0.48 — trading 42.8% below its estimated fair value. The current Other Current Assets is A$1.93 Mil. Cyclopharm's overall GF Score™ is 45/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Assets calculated?
Other Current Assets is calculated from a company's financial statements. For Cyclopharm (ASX:CYC), the current Other Current Assets is A$1.93 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cyclopharm (ASX:CYC) Overvalued in 2026?

Based on GuruFocus' analysis, Cyclopharm stock appears to be undervalued. The current stock price of A$0.48 is trading 42.8% below its estimated GF Value™ of A$0.83. GuruFocus considers Cyclopharm to be Possible Value Trap.

Key valuation signals for ASX:CYC:

  • Other Current Assets: A$1.93 Mil
  • GF Value™: A$0.83 vs. price of A$0.48 (42.8% below fair value)
  • GF Score™: 45/100 with 7 warning signs

No single metric tells the full story. See the ASX:CYC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Cyclopharm Business Description

Address 1 The Crescent, Unit 4, Kingsgrove, Sydney, NSW, AUS, 2208
Cyclopharm Ltd is a health technology company offering solutions related to functional lung ventilation imaging. Its proprietary product Technegas is a broad-spectrum diagnostic lung imaging technology product for the visualisation of pulmonary ventilation and lung function. The company sells its products to healthcare institutions and medical professionals. Maximum revenue is generated from its Technegas products and services, which include the sale of diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism and other respiratory conditions. Geographically, the company generates maximum revenue from its business in Europe, and the rest from Asia Pacific, Canada, the USA, and other regions.
45GF Score

Get the complete analysis for ASX:CYC

Other Current Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.48
Price
A$0.83
GF Value